[go: up one dir, main page]

MX2018015208A - Andrografolido para tratar formas progresivas de esclerosis multiple. - Google Patents

Andrografolido para tratar formas progresivas de esclerosis multiple.

Info

Publication number
MX2018015208A
MX2018015208A MX2018015208A MX2018015208A MX2018015208A MX 2018015208 A MX2018015208 A MX 2018015208A MX 2018015208 A MX2018015208 A MX 2018015208A MX 2018015208 A MX2018015208 A MX 2018015208A MX 2018015208 A MX2018015208 A MX 2018015208A
Authority
MX
Mexico
Prior art keywords
multiple sclerosis
andrographolid
progressive forms
treat progressive
treat
Prior art date
Application number
MX2018015208A
Other languages
English (en)
Other versions
MX386393B (es
Inventor
O Hancke Juan
Original Assignee
Innobioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innobioscience Llc filed Critical Innobioscience Llc
Publication of MX2018015208A publication Critical patent/MX2018015208A/es
Publication of MX386393B publication Critical patent/MX386393B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/19—Acanthaceae (Acanthus family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

El Andrografólido de 240 mg/día oralmente es el primer tratamiento que muestra formas progresivas significativamente benéficas de Esclerosis Múltiple en pacientes humanos.
MX2018015208A 2016-06-08 2017-06-08 Andrografólido para tratar formas progresivas de esclerosis múltiple. MX386393B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662347218P 2016-06-08 2016-06-08
PCT/US2017/036463 WO2017214346A1 (en) 2016-06-08 2017-06-08 Andrographolide treats progressive forms of multiple sclerosis

Publications (2)

Publication Number Publication Date
MX2018015208A true MX2018015208A (es) 2019-09-19
MX386393B MX386393B (es) 2025-03-18

Family

ID=60578163

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018015208A MX386393B (es) 2016-06-08 2017-06-08 Andrografólido para tratar formas progresivas de esclerosis múltiple.

Country Status (8)

Country Link
US (1) US10722492B2 (es)
EP (1) EP3468553B1 (es)
JP (2) JP6928963B2 (es)
CN (1) CN109562097B (es)
CA (1) CA3026770C (es)
DK (1) DK3468553T3 (es)
MX (1) MX386393B (es)
WO (1) WO2017214346A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019126759A1 (en) * 2017-12-22 2019-06-27 Convelo Therapeutics, Inc. Compounds and methods of promoting myelination
CN109223770A (zh) * 2018-11-14 2019-01-18 株洲千金药业股份有限公司 一种具有镇痛作用的化合物及其在制备镇痛药物中的应用
CN109293607A (zh) * 2018-11-14 2019-02-01 株洲千金药业股份有限公司 一种具有抗炎作用的化合物及其在制备抗炎药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002360696A1 (en) * 2001-12-21 2003-07-30 Ilex Oncology, Inc. Combination comprising anti-cd52 antibodies and other therapeutic agents for treatment for multiple sclerosis
BRPI0418053A (pt) * 2004-02-03 2007-04-17 Univ Austral De Chile composição de labdano diterpenos extraìdos a partir de andrographis paniculata, util para o tratamento de doenças autoimunes, e doença de alzheimer por ativação de receptores ppr-gama
AU2012359081B2 (en) 2011-12-21 2015-09-17 Innobioscience, Llc Combination therapy with interferon and andrographolides for multiple sclerosis

Also Published As

Publication number Publication date
JP2019517550A (ja) 2019-06-24
JP2021165304A (ja) 2021-10-14
DK3468553T3 (da) 2023-07-03
CN109562097B (zh) 2022-06-07
CA3026770C (en) 2024-05-28
US10722492B2 (en) 2020-07-28
CA3026770A1 (en) 2017-12-14
WO2017214346A1 (en) 2017-12-14
CN109562097A (zh) 2019-04-02
JP6928963B2 (ja) 2021-09-01
US20190083458A1 (en) 2019-03-21
MX386393B (es) 2025-03-18
EP3468553B1 (en) 2023-05-24
EP3468553A4 (en) 2020-02-12
EP3468553A1 (en) 2019-04-17

Similar Documents

Publication Publication Date Title
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
CL2019001685A1 (es) Composiciones de aminoácidos y métodos para el tratamiento de enfermedades y trastornos musculares.
CL2018003588A1 (es) Uso de inhibidores de miostatina y terapias de combinación.
AR113881A1 (es) Composiciones y métodos para el tratamiento de desórdenes inmunes usando la cepa blautia
DOP2017000097A (es) Composiciones y métodos de uso para tratar trastornos metabólicos
CL2017001893A1 (es) Uso de prg4 como agente antiinflamatorio
CO2017013443A2 (es) Composiciones que comprenden cepas bacterianas del género blautia
CO2019007205A2 (es) Usos terapéuticos de un polvo de insectos
MX2015013948A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
MX390627B (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
MX2017014544A (es) Tratamientos del cáncer.
MX380252B (es) Crenezumab para usarse en el tratamiento de enfermedad de alzheimer.
GT201600002A (es) Bencil-1h-pirazolo[3,4-b]piridinas y su uso
MX395231B (es) Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de hígado graso, y uso de los mismos.
MX388722B (es) Compuestos para tratar el cancer de ovario.
MX2018012285A (es) Metodos de tratamiento para enfermedades colestasicas y fibroticas.
SV2018005783A (es) 5,6,7,8-tetrahidro[1,2,4]triazolo[4,3-a]piridin-3(2h)-onas y 2,5,6,7-tetrahydro-3h-pyrrolo[2,1-c][1,2,4]triazol-3-ones sustituidas su uso
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
MX379359B (es) Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
MX392754B (es) Seleccion de cepas bacterianas utiles en el tratamiento de la alergia.
MX2018015208A (es) Andrografolido para tratar formas progresivas de esclerosis multiple.
NI201900023A (es) 1 - arilnaftiridin-3-carboxamidas 7-sustituidas y su uso
ECSP23091984A (es) Compuestos y usos de estos
CL2021000660A1 (es) Compuestos quelantes de hierro para tratar condiciones estéticas de la piel
EA201791819A1 (ru) Комбинированная терапия с применением конъюгата антитела против cd19 с лекарственным средством и винкристина